Résumé IA · arXiv: 1608.07499v1 · q-bio.NC
Stem Cell Therapy for Alzheimer's Disease
Posez des questions sur cet article à notre assistant IA
Comment discuter avec cet article ? Guide illustré
Vous pouvez aussi discutez avec plusieurs papiers à la fois ici.
Gardez cette conversation — un compte gratuit conserve vos questions et réponses, vos collections d’articles et vos alertes.
Continuer avec Google Créer un compte gratuitOutils pour cet article
Outils avancés Premium
Pour suivre un domaine de près : alertes de citations, diapositives de journal club, comparaison des versions et envoi vers Zotero. Découvrir Premium
Les articles autour de celui-ci
Les voir sur une carteClassés selon la proximité de leur titre et de leur résumé avec ceux de cet article. Sélectionnez-en pour les lire ensemble.
Les articles les plus proches
-
Stem Cell-based Therapeutic and Diagnostic Approaches in Alzheimer's DiseaseSadaf Abdi, Nima Javanmehr, Maryam Ghasemi-Kasman et al. · 2021 · Current Neuropharmacology · cité 19 fois · Pas encore résumé
Résumé scientifique
Background: Alzheimer's disease (AD) is a neurodegenerative impairment mainly recognized by memory loss and cognitive deficits. However, the current therapies against AD are mostly limited to palliative medications, prompting researchers to investigate more efficient therapeutic approaches for AD, such as stem cell therapy. Recent evidence has proposed that extensive neuronal and synaptic loss and altered adult neurogenesis, which is perceived pivotal in terms of plasticity and network maintenance, occurs early in the course of AD, which exacerbates neuronal vulnerability to AD. Thus, regeneration and replenishing the depleted neuronal networks by strengthening the endogenous repair mechanis…
-
New Prospects for Stem Cell Therapy in Alzheimer’s DiseaseKun Jiang, Yongqi Zhu, Lei Zhang · 2021 · Hippocampus · cité 1 fois · Pas encore résumé
Résumé scientifique
Alzheimer’s disease (AD) is a kind of neurodegenerative disease with insidious onset and progressive progression. The etiology of AD may be related to the loss of neurons, astrocytes, and microglial in the nervous system. Exogenous stem cell transplantation has brought hope to the treatment of AD. Stem cell transplantation can reduce amyloid β-protein (Aβ) deposition and Tau phosphorylation, and provide secretory factor support to improve learning and memory deficits. The purpose of this review is to provide an overview of the relationship between different stem cell species and the treatment of AD, and also summarize current experimental stem cell therapy strategies and their potential clin…
-
The past and present of therapeutic strategy for Alzheimer’s diseases: potential for stem cell therapyMasanori A. Murayama · 2023 · Experimental animals · cité 9 fois · Pas encore résumé
Résumé scientifique
Alzheimer’s disease (AD), a progressive neurodegenerative disease characterized by cognitive dysfunction and neuropsychiatric symptoms, is the most prevalent form of dementia among the elderly. Amyloid aggregation, tau hyperphosphorylation, and neural cell loss are the main pathological features. Various hypotheses have been proposed to explain the development of AD. Some therapeutic agents have shown clinical benefits in patients with AD; however, many of these agents have failed. The degree of neural cell loss is associated with the severity of AD. Adult neurogenesis, which governs cognitive and emotional behaviors, occurs in the hippocampus, and some research groups have reported that neu…
-
Mesenchymal Stem Cell Therapy for Alzheimer's DiseaseA. E. Hernández, E. García · 2021 · Stem Cells International · cité 73 fois · Pas encore résumé
Résumé scientifique
Alzheimer's disease (AD) is a neurodegenerative disease responsible for 60-70% of the 50 million cases of dementia worldwide. It is characterized by neuronal cell death, shrinkage of brain tissue, and progressive cognitive, motor, and behavioral impairment, which often leads to death. Although current treatment has helped improve the patient's quality of life, it has not been able to alter the underlying disease pathology of AD. Studies have shown that mesenchymal stem cells (MSCs)—a group of multipotent stem cells—have the ability to stimulate neuroregeneration and inhibit disease progression. More recently, extracellular vesicles (EVs) from cytokine-preconditioned MSCs have also shown to i…
-
Stem cell-based therapeutic strategies for down syndrome and Alzheimer’s diseaseOsama Hamadelseed, T. Skutella · 2025 · Stem cell research & therapeutics · cité 3 fois · Pas encore résumé
Résumé scientifique
Down syndrome (DS) and Alzheimer’s disease (AD) are two distinct yet interconnected neurological conditions that share overlapping pathological features, including amyloid-beta plaque accumulation, neuroinflammation, and progressive neurodegeneration. Individuals with DS are at increased risk of developing AD-like dementia owing to the overexpression of the amyloid precursor protein-encoding gene on chromosome 21. Despite significant research efforts, effective disease-modifying treatments remain unavailable for both conditions, necessitating the exploration of novel therapeutic approaches. We analyzed and synthesized the existing literature on stem cell therapy as a treatment for DS and AD.…
-
The application of patient-derived induced pluripotent stem cells for modeling and treatment of Alzheimer’s diseaseF. Han, Chuanguo Liu, Jin Huang et al. · 2019 · Brain Science Advances · cité 14 fois · Pas encore résumé
Résumé scientifique
Alzheimer’s disease (AD) is the most prevalent age-related neurodegenerative disease which is mainly caused by aggregated protein plaques in degenerating neurons of the brain. These aggregated protein plaques are mainly consisting of amyloid β (Aβ) fibrils and neurofibrillary tangles (NFTs) of phosphorylated tau protein. Even though the transgenic murine models can recapitulate some of the AD phenotypes, they are not the human cell models of AD. Recent breakthrough in somatic cell reprogramming made it available to use induced pluripotent stem cells (iPSCs) for patientspecific disease modeling and autologous transplantation therapy. Human iPSCs provide alternative ways to obtain specific hum…
-
An overview of stem cell-based therapy towards the treatment of Alzheimer’s diseaseSan-Chi Chen · 2023 · International Conference on Biological Engineering and Medical Science · cité 1 fois · Pas encore résumé
Résumé scientifique
The classic pharmacological approach toward Alzheimer’s disease treatment uses acetylcholinesterase inhibitors (AChEIs), where patients’ behavior and cognitive symptoms can be treated. However, the pharmacological approaches available can only relieve patients’ symptoms to some extent instead of acting as a cure. With the recent advancements in regenerative medicine, extensive pre-clinical studies have been conducted to test if stem cell therapy can be a cure for Alzheimer’s disease. The stem cell type being investigated through the treatment of Alzheimer’s disease includes embryonic stem cells (ESCs), induced pluripotent stem cells (iPSCs), mesenchymal stem cells (MSCs), and neural stem cel…
-
Intranasal administration of induced pluripotent stem cell-derived cortical neural stem cell-secretome as a treatment option for Alzheimer’s diseaseH. Mo, Juryun Kim, J. Kim et al. · 2023 · Translational Neurodegeneration · cité 17 fois · Pas encore résumé
Résumé scientifique
Background Alzheimer’s disease (AD) is the most common neurodegenerative disorder in the elderly, resulting in gradual destruction of cognitive abilities. Research on the development of various AD treatments is underway; however, no definitive treatment has been developed yet. Herein, we present induced pluripotent stem cell (iPSC)-derived cortical neural stem cell secretome (CNSC-SE) as a new treatment candidate for AD and explore its efficacy. Methods We first assessed the effects of CNSC-SE treatment on neural maturation and electromagnetic signal during cortical nerve cell differentiation. Then to confirm the efficacy in vivo, CNSC-SE was administered to the 5×FAD mouse model through the…
Les travaux antérieurs sur lesquels il s’appuie
-
Probing sporadic and familial Alzheimer’s disease using induced pluripotent stem cellsMason A. Israel, Shauna H. Yuan, C. Bardy et al. · 2012 · Nature · cité 1 257 fois · Pas encore résumé
Résumé scientifique
Our understanding of Alzheimer’s disease pathogenesis is currently limited by difficulties in obtaining live neurons from patients and the inability to model the sporadic form of the disease. It may be possible to overcome these challenges by reprogramming primary cells from patients into induced pluripotent stem cells (iPSCs). Here we reprogrammed primary fibroblasts from two patients with familial Alzheimer’s disease, both caused by a duplication of the amyloid-β precursor protein gene (APP; termed APPDp), two with sporadic Alzheimer’s disease (termed sAD1, sAD2) and two non-demented control individuals into iPSC lines. Neurons from differentiated cultures were purified with fluorescence-a…
-
Modeling familial Alzheimer's disease with induced pluripotent stem cells.T. Yagi, D. Ito, Y. Okada et al. · 2011 · Human Molecular Genetics · cité 588 fois · Pas encore résumé
-
Alzheimer’s Disease: The Challenge of the Second CenturyD. Holtzman, J. Morris, A. Goate · 2011 · Science Translational Medicine · cité 1 436 fois · Pas encore résumé
Résumé scientifique
In the first of our State of the Art Review series, David M. Holtzman, John C. Morris, and Alison M. Goate explore the rapid pace of Alzheimer’s disease research and the challenges to translating research breakthroughs into clinical treatments. Alzheimer’s disease (AD) was first described a little more than 100 years ago. It is the most common cause of dementia with an estimated prevalence of 30 million people worldwide, a number that is expected to quadruple in 40 years. There currently is no effective treatment that delays the onset or slows the progression of AD. However, major scientific advances in the areas of genetics, biochemistry, cell biology, and neuroscience over the past 25 year…
-
Oxidative Stress in Alzheimer's Disease: Why Did Antioxidant Therapy Fail?Torbjörn Persson, B. Popescu, A. Cedazo-Mínguez · 2014 · Oxidative Medicine and Cellular Longevity · cité 330 fois · Pas encore résumé
Résumé scientifique
Alzheimer's disease (AD) is the most common form of dementia in the elderly, with increasing prevalence and no disease-modifying treatment available yet. A remarkable amount of data supports the hypothesis that oxidative stress is an early and important pathogenic operator in AD. However, all clinical studies conducted to date did not prove a clear beneficial effect of antioxidant treatment in AD patients. In the current work, we review the current knowledge about oxidative stress in AD pathogeny and we suggest future paths that are worth to be explored in animal models and clinical studies, in order to get a better approach of oxidative imbalance in this inexorable neurodegenerative disease…
-
Genetic Aspects of Alzheimer DiseaseJ. Williamson, J. Goldman, K. Marder · 2009 · The Neurologist · cité 299 fois · Pas encore résumé
Résumé scientifique
Background:Alzheimer disease (AD) is a genetically complex disorder. Mutations in 3 genes, presenilin 1, amyloid precursor protein, and presenilin 2, lead to early-onset familial AD in rare families with onset of disease occurring prior to age 65. Specific polymorphisms in apolipoprotein E are associated with the more common, late-onset AD occurring after age 65. In this review, we discuss current advances in AD genetics, the implications of the known AD genes, presenilin 1, presenilin 2, amyloid precursor protein, and apolipoprotein E, and other possible genes on the clinical diagnosis, treatment, and genetic counseling of patients and families with early- and late-onset AD. Review Summary:…
Les articles qui le citent
-
Potential Stem Cell Treatment for Alzheimer’s Disease with Possible Applications of Lithium TherapyCaputo Tj, Inayat Ms, Gallicchio Vs · 2024 · Journal of Clinical and Laboratory Medicine · Pas encore résumé
Résumé scientifique
Alzheimer’s disease is characterized by progressive cognitive decline, including memory loss, impaired judgment, and changes in behavior. It is the most common cause of dementia and is known to generate pathological changes in the brain, such as amyloid plaques and neurofibrillary tangles which contribute to the symptoms. This disease affects over 55 million people worldwide and is known to frequently develop around the age of 65 and older. Bipolar disorder is characterized by extreme mood swings that include periods of mania involving heightened energy, euphoria, and depressive episodes leading to a loss of interest in many activities. These mood shifts can significantly impact the daily li…
-
Nanoparticles-based anti-aging treatment of Alzheimer’s diseaseJianjian Chu, Wenbo Ji, Jian-hua Zhuang et al. · 2022 · Drug Delivery · cité 22 fois · Pas encore résumé
Résumé scientifique
Abstract Age is the strongest risk factor for Alzheimer’s disease (AD). In recent years, the relationship between aging and AD has been widely studied, with anti-aging therapeutics as the treatment for AD being one of the mainstream research directions. Therapeutics targeting senescent cells have shown improvement in AD symptoms and cerebral pathological changes, suggesting that anti-aging strategies may be a promising alternative for AD treatment. Nanoparticles represent an excellent approach for efficiently crossing the blood-brain barrier (BBB) to achieve better curative function and fewer side effects. Thereby, nanoparticles-based anti-aging treatment may exert potent anti-AD therapeutic…
-
Mesenchymal stromal cells (MSCs) for neurodegenerative disease: A promising frontier.A. Shariati, R. Nemati, Yasin Sadeghipour et al. · 2020 · European Journal of Cell Biology · cité 73 fois · Pas encore résumé
Résumé scientifique
Neurodegenerative disorders are a variety of diseases including Alzheimer's (AD), Parkinson's (PD), and Huntington's diseases (HD), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) along with some other less common diseases generally described by the advanced deterioration of central or peripheral nervous system, structurally or functionally. In the last two decades, mesenchymal stromal cells (MSCs) due to their unique assets encompassing self-renewal, multipotency and accessibility in association with low ethical concern open new frontiers in the context of neurodegenerative diseases therapy. Interestingly, MSCs can be differentiated into endodermal and ectodermal lineages (e…
-
Past, present and future of therapeutic strategies against amyloid-β peptides in Alzheimer's disease a systematic review.D. Jeremic, Lydia Jiménez-Díaz, J. Navarro-López · 2021 · Ageing Research Reviews · cité 252 fois · Pas encore résumé
Résumé scientifique
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease in ageing, affecting around 46 million people worldwide but few treatments are currently available. The etiology of AD is still puzzling, and new drugs development and clinical trials have high failure rates. Urgent outline of an integral (multi-target) and effective treatment of AD is needed. Accumulation of amyloid-β (Aβ) peptides is considered one of the fundamental neuropathological pillars of the disease, and its dyshomeostasis has shown a crucial role in AD onset. Therefore, many amyloid-targeted therapies have been investigated. Here, we will systematically review recent (from 2014) investigational, follow-up and…
-
Stem cells in central nervous system diseases: Promising therapeutic strategies.Caidi Ying, Jia-Hao Zhang, Hao-Cheng Zhang et al. · 2023 · Experimental Neurology · cité 22 fois · Pas encore résumé
Résumé scientifique
Central nervous system (CNS) diseases are a leading cause of death and disability. Due to CNS neurons have no self-renewal and regenerative ability as they mature, their loss after injury or disease is irreversible and often leads to functional impairments. Unfortunately, therapeutic options for CNS diseases are still limited, and effective treatments for these notorious diseases are warranted to be explored. At present, stem cell therapy has emerged as a potential therapeutic strategy for improving the prognosis of CNS diseases. Accumulating preclinical and clinical evidences have demonstrated that multiple molecular mechanisms, such as cell replacement, immunoregulation and neurotrophic ef…
Aller plus loin
Comment ces articles sont-ils trouvés ?
Nous comparons le titre et le résumé de cet article avec ceux de tous les articles résumés sur ce site, et avec les articles que Semantic Scholar recommande, ceux qu’il cite et ceux qui le citent (pour un article très cité, ses citations les plus récentes et, depuis OpenAlex, les plus citées). Parmi les travaux antérieurs et les suites, les articles qui s’utilisent en profondeur, une méthode qu’il utilise et les suites très citées remontent un peu. Les niveaux (très proche, proche, apparenté) viennent de la similarité des textes, pas d’un jugement de qualité ; * signale un article sans résumé, comparé par son titre. La phrase sous un article est écrite par une IA à partir des deux résumés : vérifiez-la dans les articles. Un article jugé hors sujet par trois lecteurs quitte la liste.
Mis à jour le 5 novembre 2026.
Le résumé précédent a été créé il y a plus d'un an et peut être réexécuté (si nécessaire) en cliquant sur le bouton Exécuter ci-dessous.
Avertissement : Notre outil de synthèse basé sur l'IA et l'assistant virtuel fournis sur ce site Web peuvent ne pas toujours fournir des résumés complets ou des réponses exactes. Nous vous encourageons à examiner attentivement et à évaluer le contenu généré pour vous assurer de sa qualité et de sa pertinence par rapport à vos besoins.